Compare Invesco NASDAQ 100 ETF (QQQM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco NASDAQ 100 ETF vs GeneDx Holdings Corp — how do they compare? Invesco NASDAQ 100 ETF trades at $309.39 (market cap $113.40B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 56.1× GeneDx Holdings Corp's market cap, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco NASDAQ 100 ETF for 54 Days and GeneDx Holdings Corp for 19 Days on average.
| QQQM | WGS | |
|---|---|---|
Market Cap | $113.40B | $2.02B |
Volume | 2,866,236 | 734,640 |
Sector | Broad Market / Factor | Health |
52-Week High | $312.76 | $167.51 |
52-Week Low | $229.87 | $34.51 |
Typical Hold Time | 54 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQM trades at $309.39, down 0.84% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF's lower 0.15% expense ratio compared to QQQ's 0.18% provides a cost advantage, though trading spreads can impact returns. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% during Q2 2026 (SEC filing, September 28, 2026).
The outlook remains positive given the Nasdaq-100's exposure to technology growth stocks, though concentration risk in top holdings and potential tax complications with covered-call alternatives like QQQI warrant caution. Market leadership from small-cap stocks within the index suggests continued momentum, but investors should monitor valuation levels given the current price near resistance at $311.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
